CD4 and lung cancer: In our study we showed that DC-based lung cancer vaccine generated in GMP-complaint serum free media with HHP-killed lung cancer cell lines and poly(I:C) exhibits functional plasticity and activity to stimulate tumor antigen-specific IFN-γ-producing CD8+ and CD4+ T cells from NSCLC patients.